Inflammatory processes and tissue scarring are characteristic features of chronic allograft nephropathy. Hepatocyte growth factor (HGF) has beneficial effects on renal fibrosis and it also ameliorates renal interstitial inflammation as it has been recently described. Contrarily to protein administration, intramuscular gene electrotransfer allows sustained release of HGF. So, here we hypothesized that gene therapy with human HGF would diminish the characteristic scarring of chronic allograft nephropathy either by antagonizing tissue fibrosis mechanisms or by reducing inflammation. Lewis rats transplanted with cold preserved Fischer kidneys received vehicle (NoHGF) or intramuscular plasmid DNA encoding HGF plus electroporation either before transplantation (IniHGF, early post-transplant cytoprotection of tubular cells) or 8/10 weeks after transplantation (DelHGF, delayed prevention of chronic mechanisms). Serum creatinine and proteinuria were measured every 4 weeks for 24 weeks. Grafts at 12 or 24 weeks were evaluated for glomerulosclerosis, fibrosis inflammatory cells and mediators, cell regeneration and tubulo-interstitial damage. Nontreated animals developed renal insufficiency, progressive proteinuria and fibrosis among other characteristic histological features of chronic allograft nephropathy. Treatment with human HGF, especially when delayed until the onset of fibrogenic mechanisms, reduced renal failure and mortality, diminished tubule-interstitial damage, induced cell regeneration, decreased inflammation, NF-jB activation, and profibrotic markers at 12 weeks and prevented late interstitial fibrosis and glomerulosclerosis. The effectiveness of HGF-gene therapy in the prevention of renal allograft scarring is related with the halt of profibrotic inflammatory-induced mechanisms. Hepatocyte growth factor (HGF) has multiple biological activities in a wide variety of cells, including renal tubular and endothelial. 1 Its expression is upregulated at early stages of chronic processes as a natural repair mechanism but sustained injury throughout these processes results in the overexpression of other growth factors that have antagonistic effects to HGF. The equilibrium between HGF and profibrotic factors is then imbalanced in favor of the latter, thereby resulting in extracellular matrix accumulation and progression to renal fibrosis. 1, 2 Protein HGF supply has been shown to prevent the onset of renal scarring by inhibiting the morphologic transformation of tubular epithelial cells. 3, 4 Recently, it has been reported that HGF is a potent antiinflammatory cytokine that decreases the RNA expression of tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g), two inflammatory cytokines 5 and directly suppresses proinflammatory membrane co-factor protein 1 (MCP-1) and RANTES expression, probably via nuclear factor-kappa B (NF-kB) in tubular epithelial cells. 6, 7 HGF also offers protection in acute ischemic and inflammatory injuries by its antiapoptotic and proangiogenic effects 8, 9 by attenuating ischemia-induced cell death 10 and ischemia-or toxic-induced acute renal failure. [11] [12] [13] [14] In human critical limb ischemia, HGF has been safely applied in phase I/early phase IIa, which indicates its usefulness as a sole therapy. 15 Gene therapy is now moving from experimental studies into clinical applications, [16] [17] [18] but gene transfer methodology is one of the limiting steps. Viral vector gene transfer has proved efficient but does not allow repetitive injection. In addition, although the administration of naked plasmid DNA or liposome formulated DNA is feasible, the levels of the therapeutic protein obtained are too low. Recently, DNA electrotransfer has greatly improved nonviral gene transfer efficiency. Electrotransfer is a classic technique used in vitro that has been adapted to experimental in vivo gene therapy. In vivo, electroporation shows consistently high levels of gene expression for many genes 19 and is normally applied after intramuscular injection ( [20] [21] [22] [23] , reviewed in André and Mir 24 ). Our group previously reported that HGF gene electrotransfer is effective to treat late stages of diabetic nephropathy. 25 Chronic allograft nephropathy (CAN) is a multifactorial process that leads to late allograft loss in renal transplantation. The joint association of nonalloreactive factors, as cold ischemia, plus allogenicity significantly increases cellular infiltration at both early and late stages, aggravating the progression of experimental CAN. [26] [27] [28] Here we tested the hypothesis that HGF electrotransfer provides protection against the inflammatory and fibrotic processes that finally leads to the characteristic features of CAN. As HGF electrotransfer allows up to 14 days increase in endogenous HGF, 25 preventive gene therapy was applied following two distinct timings: before renal transplantation for the early post-transplant cytoprotection from ischemia-reperfusion injury, or at 8 and 10 weeks after transplantation for the delayed prevention of chronic mechanisms.
RESULTS

HGF in CAN
Ten out of 26 NoHGF rats did not survive the study period ( Figure 1 ) and died of renal insufficiency. The surviving rats developed progressive proteinuria (Figure 2b ) along the follow-up with renal insufficiency from the 16th week ( Figure 2a) .
Rat HGF plasma levels in this model of kidney transplant were found lower than those in rats with two native kidneys ( Figure S1B ) (week 16: 7.2971.68 ng/ml; week 32: 6.2071.80 ng/ml). 25 The profile of plasma rat HGF level in NoHGF rats decreased with the progression of CAN. Levels were higher at 4 weeks and dropped afterwards (Figure 3 Initial HGF Delayed HGF Figure 3 | Plasma rat HGF protein kinetics. Here, the NoHGF group showed an initial rapid decrease in rat HGF plasma levels, while in the IniHGF group these levels decreased slowly and progressively. In the DelHGF group, plasma rat HGF increased after treatment and reached the highest levels at the end of the study compared with the other groups. Analysis of variance, Fisher's test, *P ¼ 0.0025 NoHGF vs DelHGF.
At 24 weeks, conventional histology (Table 1a, Figure 4 ) revealed interstitial fibrosis, tubular atrophy, a considerable percentage of sclerosed glomeruli as well as a high number of interstitial a-smooth muscle actin (a-SMA) ( Figure 4 ) and tubular and glomerular connective tissue growth factor (CTGF)-positive cells (Table 1b, Figure 4 ). In addition to these fibrotic changes, inflammation was also present, with macrophages and T cells infiltrating kidneys. This cell infiltration was already notable at 12 weeks ( Figure 5 ).
The reverse transcription-polymerase chain reaction results showed that tissue expression of the rHGF gene did not vary between 12 and 24 weeks ( Table 3) . As results were expressed as many fold with respect to nontransplanted healthy kidneys (data not shown), values o1 in NoHGF samples indicate that rat HGF gene expression was reduced in CAN. Tissue rHGF protein in NoHGF grafts was lower at the end of the study than at 12 weeks, although differences did not reach statistical significance.
Effect of initial treatment with hHGF gene therapy on CAN Animals from the IniHGF group had a higher survival rate than those from the NoHGF group. Interestingly, initial treatment with HFG delayed death by 8 weeks, after which time only four of the 16 rats died, from renal insufficiency (Figure 1 ). Rats in the IniHGF group developed only slight proteinuria or renal insufficiency (Figure 2 ).
Here, one single intervention with our gene therapy approach allows high human HGF plasma levels (460 pg/ml day 6; 90 pg/ml day 11) as previously shown. 22 The profile of endogenous rat HGF plasma levels in the IniHGF group during the first weeks did not drop as dramatically as in the NoHGF group but continued decreasing along time ( Figure 3 ). The tissue expression of rat HGF gene and rat HGF protein content was similar in the IniHGF and NoHGF groups (Table 3) .
At 24 weeks, the conventional histology showed neither vasculopathy nor glomerulosclerosis in any of them and few signs of both fibrosis and infiltrating cells (Table 1a, Figure 4 ). Immunohistochemistry revealed a clear reduction in the deposition of the fibrotic markers a-SMA and CTGF (Table 1b, Figure 4 ).
Effect of delayed treatment with hHGF gene therapy on CAN
The DelHGF group had a better survival rate than the NoHGF group as only three out of 16 rats died from renal insufficiency ( Figure 1 ). Interestingly, there was no mortality during the 8 weeks after HGF electrotransfer, similarly to IniHGF group. Rats in the DelHGF group displayed normal and stable renal function throughout the entire follow-up, in a similar manner to the IniHGF group. Despite no statistical difference, at 24 weeks, creatinine and proteinuria were lower in the DelHGF than in the IniHGF group ( Figure 2 ). o r i g i n a l a r t i c l e
Two courses of gene electrotransfer effectively resulted in detectable human HGF plasma levels at 12 weeks (DelHGF: 141799 pg/ml; NoHGF: 070 pg/ml, Po0.05).
In constrast to the NoHGF and IniHGF groups, endogenous rat HGF plasma levels in the DelHGF group increased significantly after human HGF electrotransfer (Figure 3a) . Thereafter, plasma rat HGF in this group experienced a parallel decrease to the other two groups. At the end of the follow-up, rat HGF gene expression and protein content in DelHGF grafts were higher than in the other groups (Table 3) .
At 24 weeks (412 weeks after HGF treatment), microscopic observation of DelHGF kidneys showed scarce lesions in renal structures without vasculopathy, glomerulosclerosis or fibrosis and only a few infiltrating cells (Table 1, Figure 4 ). Figures 4 and 5) . In addition to interstitial infiltrate, the inflammatory cytokines IL12b, TNF-a, and INF-g were overexpressed at 12 weeks (Table 2 ).
In the DelHGF group, renal tissue 1 month after treatment not only showed less interstitial fibrosis but a reduced number of all kinds of infiltrating cells, and displayed similar values to those observed at 8 weeks in nontreated kidneys (Table 1, Figures 4 and 5 ). In parallel with the few infiltrating cells, HGF-treated kidneys at 12 weeks had clearly less expression of inflammatory cytokines than NoHGF kidneys ( Table 2 ). To further assess inflammatory mechanisms, we evaluated NF-kB expression. In nontreated kidneys, NF-kB p65 subunit was widely found in epithelial tubular cells following both a nuclear and cytoplasmic pattern, wheras there was only faint cytoplasmatic staining in DelHGF kidneys and no nuclear staining ( Figure 5 ). Differences were also seen at mRNA level (RelA), although here there was no statistical significance (Table 2 , see Figure S1A ).
At 12 weeks, hHGF gene electrotransfer reduced transforming growth factor-b (TGF-b) expression while slightly increased rHGF, all resulting in a greater HGF/TGF-b ratio (Table 3) . At this moment, glomerulosclerosis and CTGFpositive cells in tubuli or in glomeruli did not differ between treated and nontreated kidneys (Table 1b) , which indicates that at 12 weeks extracellular matrix deposition was moderate and it was not modified by HGF treatment. In contrast, at 24 weeks, TGF-b expression (Table 3) was reduced in DelHGF kidneys and CTGF deposition was observed only in NoHGF grafts (Table 1b, Figure 4) . In addition, a-SMA deposition was already manifested at 12 weeks in nontreated kidneys and, importantly, HGF treatment clearly reduced the number of a-SMA-positive cells both at 12 and 24 weeks (Figure 4 ). Besides this clear difference in fibrotic markers, there also exists difference with respect to regeneration at 12 weeks. The PCNA gene expression was reduced in the NoHGF group whereas it was significantly increased in HGF-treated kidneys (Table 3) .
DISCUSSION
We have shown that treatment with HGF modifies the natural outcome of chronic allograft nephropathy. One of the contributions of the present study is the innovative nonviral intramuscular gene electrotransfer used rather than the classical HGF protein supplement. 29 Gene therapy appears to be the alternative to avert the half-life handicap of protein HGF. 30 One single intervention with our gene therapy approach allows high human HGF plasma levels up to 14 days 22 and increases endogenous rat HGF plasma and tissue levels. 25 The normal creatinine kinase levels of our electropored rats ruled out the possibility of muscle damage indicating the safety of the in vivo electroporation.
As a physiological mediator of tissue repair, endogenous HGF increases after ischemic insult or acute rejection 31 and decreases in chronic processes. 1, 32 In our CAN model, the highest rat HGF plasma levels were found early after transplantation, when the kidneys were still under the late effects of acute ischemic-induced inflammatory processes. A rapid decrease in plasma HGF was observed as renal The gene expression of NF-kB p65 subunit (RelA), interleukin-12b (IL-12b), tumor necrosis factor-alpha (TNF-a) and interferon-gamma (INF-g) were quantified by RTreal-time PCR on 12-week tissue samples and results expressed as 'many fold' with respect to control healthy nontransplanted kidneys (see Figure S1A) .
Po0.05 vs NoHGF. RelA expression was 1.6 fold-reduced by HGF electrotransfer. The assessed proinflammatory cytokines were over-expressed in all kidney allografts but this expression was 2-3-fold reduced in treated kidneys. at 24 weeks Po0.05 vs IniHGF. The expression of the profibrotic factor TGF-b was reduced early after HGF treatment, at 12 weeks, resulting in an increase of HGF/TGF-b, suggestive of regeneration. This is confirmed by the PCNA expression, a cell proliferation marker, which was significantly increased in HGF-treated animals. ELISA, enzyme-linked immunosorbent assay; HGF, hepatocyte growth factor; TGF-b, transforming growth factor. damage became apparent and, at 24 weeks, endogenous HGF gene expression fell below normal values. The decrease in HGF is closely related to the destruction of tubular epithelial cells, 33 so the chronic renal fibrosis and tubular atrophy observed may, in part, account for the decrease in HGF. Thus, the rationale of HGF supplementation to exert a therapeutic action in CAN is justified.
The other novelty is the treatment delivery following two distinct timing schedules, before transplantation for early post-transplant cytoprotection of tubular cells during ischemic injury, and delayed delivery for the prevention of chronic mechanisms. The natural course of human CAN begin as early as a few weeks after transplantation. 34 Clinical protocol biopsies at 4 months have detected a significant number of stable allografts that histologically have characteristic features of CAN. 35 As protocol biopsies allow the recognition of early affected kidneys, they offer the possibility to initiate early treatment. We did not attempt to turn back advanced CAN because the treatment of established nephropathies with severe renal insufficiency, proteinuria, and scarring is rarely successful. Instead, we applied preventive treatment in an attempt to find a therapy with potential clinical benefits.
The profile of cytokine expression in experimental CAN has been well described. 36, 37 After the initial inflammatory burst, a relative period of quiescence occurs. Thereafter a progressive macrophage infiltration between 12 and 16 weeks reappears with macrophage-associated products such as TNF-a and INF-g. Simultaneously, functional and structural chronic changes begin to manifest. 37 When we performed HGF gene electrotransfer just before transplant, we aimed to diminish ischemia-reperfusion mechanisms and, effectively, late renal protection was achieved. Some studies report the potential mechanisms of early beneficial effect of HGF on ischemic injury. Nakamura et al. 8 and Jayasankar et al.
9
demonstrated the cardioprotective effect of HGF by reducing ischemia-induced angiogenesis and apoptosis. Arthur et al.
5
showed that HGF reduced microscopic bowel inflammation, which indicates that the beneficial effect of HGF is attributable to a direct anti-inflammatory action. We have previously shown in a model of renal warm ischemia that HGF gene therapy prevents the early postischemic damage by reducing apoptosis and inflammation and by fostering regenerative processes at 1 week. 23 Here, we show that the treatment of initial ischemia-reperfusion injury with HGF electrotransfer also offers late benefits on CAN.
Like initial treatment, delayed hHGF electrotransfer effectively attenuated the development of CAN because in addition to reduced mortality and better renal function, chronic renal damage was notably diminished at 24 weeks. Interestingly, glomeruloesclerosis, tubular atrophy, and interstitial infiltrate did not differ between 24 and 12 weeks, just after gene therapy, indicating that renal scarring had already been arrested at 12 weeks by HGF-delayed treatment. The exact mechanism by which this delayed HGF administration counteracts the progression of CAN is a matter of discussion. In concordance with current data, here we abrogate for two nonexcluding hypotheses. On the one hand, through the proregenerative effects of HGF, which acts in a reciprocal manner to TGF-b, which favors the fibrotic mechanisms, [1] [2] [3] [4] 38 and, on the other, through its beneficial effects on inflammatory injury. [5] [6] [7] [8] [9] [10] 23 As early as 12 weeks, TGF-b, a-SMA, and tubular CTGF were already enhanced in nontreated kidneys but no glomerulosclerosis or vasculopathy were observed. Delayed hHGF electrotransfer clearly decreased TGF-b, increased HGF/TGF-b ratio and PCNA expression indicating that cell regeneration has been activated. Simultaneously, the number of transforming cells expressing a-SMA as well as CTGF was reduced. Interestingly, this reduction was still present at 24 weeks. Transformation to a-SMA þ cells from tubular cells is believed to be a central event in the progression of chronic renal fibrosis 8 as myofibroblast activation is a predictor of renal disease progression. Therefore, it is reasonable to conjecture that HGF preserved the tubular epithelial cell phenotype by blocking epithelial-to-mesenchymal transition. In addition to tubulo-interstitial fibrosis, glomerular CTGF was also enhanced at 12 weeks in NoHGF kidneys, with a further increase at 24 weeks in parallel to glomeruloesclerosis. Again, we found a consistent therapeutic effect of HGF because a downregulation of glomerular CTGF and subsequent extracellular matrix deposition in glomeruli had occurred, as reported in diabetic nephropathy. 25 In addition to the antifibrotic effect, a novel action has been attributed to HGF, the amelioration of renal interstitial inflammation. 6 Our results show that, at 12 weeks, delayed HGF treatment inhibited inflammatory cell infiltration, reducing macrophages, CD3 þ , B-and T-cell lymphocytes, and their related cytokines IL12, TNF-a, and IFN-g. Other authors 6, 7 have reported this anti-inflammatory effects showing that HGF directly suppresses proinflammatory cytokine expression via NF-kB in tubular epithelial cells. Our results also indicate that HGF reduces NF-kB activation as it hindered its overexpression and its translocation to the nuclei in tubular epithelial cells of treated kidneys. Mononuclear cells are crucial sources of profibrotic molecules, products that may alter the function of contractile mesangial cells in the glomeruli, thereby causing the overproduction of the mesangial matrix 37 and also activating interstitial resident fibroblasts, thus promoting epithelial-to-mesenchymal transition leading to renal scarring. Blockade of this cell infiltration in the DelHGF group effectively controlled later profibrotic mechanisms and these animals showed less glomerulosclerosis and interstitial fibrosis, thereby resulting in the attenuation of CAN. Despite the spontaneous reduction of cell infiltration at 24 weeks, renal damage progressed in NoHGF kidneys, indicating that the beneficial effects of HGF also reside in the blockade of profibrotic inflammatory-induced mechanisms.
In conclusion, here we show that HGF gene therapy is consistently effective in the prevention of renal allograft fibrosis. It could be said that this is especially true when administration is delayed until the onset of fibrogenic mechanisms. Someone can argue that the difference could be derived from two HGF courses vs one. However, the rationale of the study was to cover two phenomena that differ in time and in duration: one initial usually brief period, and a later, longer, and undefined one. This amelioration is related, at least in part, to the reduction of profibrotic inflammatory processes. The opportunity offered by accurate clinical follow-up or protocol biopsies to identify patients who present incipient features of CAN allows a more personalized treatment of this chronic kidney disease. Thus, the delayed safety gene electrotransfer used here should be clinically more applicable than a systematic pretransplant approach.
MATERIALS AND METHODS Animals and renal transplantation
For renal transplantation, inbred male Lewis rats received a kidney from Fischer rats (250 g BW, Charles River by Harlan UK Limited, Bicester, UK) as previously described. 26 Kidneys were preserved for 2.5 h in EuroCollins at 41C. Animals received a single daily dose of 5 mg/kg cyclosporine (Sandimmun Neoral, Novartis, Spain) by oral gavage for 15 days. On day 7, right native nephrectomy was performed. All the procedures and housing conditions were in accordance with the Guidelines of the Committee on the Care and Use of Laboratory Animals and Good Laboratory Practice.
Gene therapy
The HGF expression vector was constructed as previously described. 22 Rats were anesthetized and plasmid was injected in SP1017 vehicle (200 ml/leg) into the tibialis anterior muscle as previously described. 22, 23 As controls, NoHGF rats were injected with an inactive plasmid in SP1017 vehicle (200 ml/leg). Afterward, an electrical field was applied to the area around the injection. 22, 23, 25 Eight pulses (20 ms, 2 Hz) were delivered at 175 V/cm. Using this methodology, human HGF plasma levels arose for 12 days (460 pg/ ml day 6; 90 pg/ml day 11) and were overexpressed in renal tissue up to 15 days after electroporation. 22 Sham or therapeutic interventions were performed in a single course, 3 or 4 days before kidney transplantation in initial treatment or two courses in the delayed treatment group, at 8 and 10 weeks after transplantation.
Plasma creatinine kinase levels (creatinine kinase ¼ 81.17 13.5 U/l) measured in 10 rats randomly selected from all groups were found among the normal range (22-198 U/l).
Study design and follow-up
Before transplantation and then monthly until the end of the study at 24 weeks, rats were weighed and placed in metabolic cages for 24 h urine and tail-vein-blood collection. Urine and serum creatinine (mmol/l) were determined by Jaffe's reaction (Beckman Instruments, Palo Alto, CA, USA), creatinine clearance (ml/min) by standard formula, and proteinuria (mg/24 h) by Ponceau's method (Bayer Diagnostics). At the end of the study, the grafted kidney was processed for histological and molecular studies.
Rats were divided into three groups: NoHGF: control group of kidney transplant injected with an inactive plasmid (n ¼ 26); IniHGF: an initial single course of HGF gene therapy delivered 3-4 days before transplantation (n ¼ 16); and DelHGF: two delayed courses of HGF gene therapy delivered on weeks 8 and 10 posttransplantation (n ¼ 16). Additional animals (n ¼ 8) included in the nontreated group were killed at 8 weeks to assess the histological progression of CAN. One month after gene therapy (3 months post-transplantation), some animals from the NoHGF and DelHGF groups (n ¼ 4, each group) were killed to further study the early mechanisms involved. The high number of animals included in the NoHGF group corresponded to the elevated post-transplant mortality.
Histology
Tissue sections (3-4 mm) were stained with hematoxylin and eosin and periodic acid Schiff methods. A pathologist, blind to the treatment groups, examined all sections for glomerular, vascular, and tubulo-interstitial lesions. For glomerulosclerosis quantification (%), the global sclerosed glomeruli of each kidney section were counted and divided by the total number. Tubular atrophy, interstitial cell infiltration, interstitial fibrosis, and vasculopathy were graded following a semiquantitative scale from 0 to þ 3 (0 denoted no abnormalities; þ 1, less than 1/3; þ 2, between 1/3 and 2/3; þ 3, more than 2/3 of the sample). A total tubulo-interstitial score was obtained by the addition of the three individual tubulointerstitial parameters.
Immunohistochemistry
Representative tissue sections were immunostained using the immunoperoxidase technique. As primary antibodies, we used monoclonal mouse anti-rat CD45RC for T/B cells (Serotec), CD3 for T cells (Serotec, Bionova cientifica, Spain), ED1 for monocyte/ macrophage (Oxford Biomarketing, Kidlington, UK), MS-113 for a-SMA (NeoMarkers, Lab Vision Ltd, UK), a rabbit polyclonal-IgG for CTGF (Santa Cruz Biotechnology Inc., CA, USA), and rabbit polyclonal anti-NF-kB p65 subunit (Abcam plc, Cambridge, UK). Horse anti-rabbit (Vector Laboratories, Burlingame, CA, USA) and anti-mouse (Pierce Biotechnology Inc., Cultek SL, Madrid, Spain) IgG were used as secondary antibodies. Samples were revealed with ABC-DAB and counterstained with hematoxylin. No primary antibodies were used for negative controls.
Positive CD45RC, CD3, and ED1 cells infiltrating kidneys, a-SMA þ interstitial cells, and CTGF þ cells in glomeruli were counted and expressed as mean7s.e.m. of cells per field of view or per glomerulus (cells/FV or cells/glom at Â 400 magnification, X20 counted fields or glomeruli per kidney). Tubuli CTGF staining was semiquantitatively scored from 0 to þ 4. Positive staining of NF-kB p65 was assessed in the cytoplasm and nucleus of tubular epithelial cells.
Determination of human and rat HGF protein levels Human plasma HGF was measured using a commercially available ELISA kit (R&D Systems, Minneapolis, USA) as previously described. 25 Rat HGF was determined by a commercially available ELISA kit (Institute of Immunology, Japan) in plasma samples (ng/ml) and renal tissue extracts (ng/mg prot) as previously described. 23, 25 Total protein concentration was measured by Bradford's method (BioRad Laboratories GmbH, München, Germany). The rat HGF antibody does not cross-react with human HGF. 39 Quantification of renal rat gene expression by reverse transcription-real-time-polymerase chain reaction Total RNA extraction and reverse transcription was performed as previously described. 26 Tissue cDNA HGF was amplified and quantified by RT-real time-PCR (ABI Prism s 7700, Applied Biosystems) using the comparative C T method. 30 The primers and probe (Table 4) to detect the target sequence of rat HGF were designed and optimized following the manufacturer's instructions. 40 The PDAR (prevedeloped TaqMan assay reagents) methodology 41 was used for rat PCNA, c-met, TGF-b, TNF-a, INF-g, IL-12b, RelA, and 18S polymerase chain reactions starting from 1 ml of each cDNA sample. Pooled values of healthy nontransplanted kidneys were used as the reference value. Results were expressed as 'many fold of the unknown sample' with respect to the reference value (arbitrary units). No polymerase chain reaction products were detected using reverse-transcribed negative controls as template.
Statistical analysis
Statistical analysis was performed using the StatView s 5 program (SAS Institute Inc., Barcelona, Spain). Survival was analyzed using the Kaplan-Meier and log-rank methods. Quantitative data were compared using analysis of variance -Scheffe's test for more than two groups and t-test for two groups. To compare groups for proteinuria, serum creatinine, and creatinine clearance throughout the follow-up, variables were compacted (cv ¼ compacted variable) and compared with analysis of variance. For histological data, Kruskall-Wallis and Connover's tests were used. For NF-kB staining evaluation, a contingency table was constructed and compared with w 2 test. Po0.05 was considered statistically significant. Data are presented as mean7s.e.m. The primers and probe to detect the target sequence of rat HGF were previously designed with the Primer Express TM software on the Gene Bank sequence X54400, and afterwards their concentrations were optimized following the manufacturer's instructions. For rat HGF, 1 ml of each cDNA sample was mixed in a total volume of 25 ml to reach a final concentration of 900 nM for both forward and reverse primers and 200 nM for the probe.
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